VERTEX PHARMACEUTICALS INC / MA Capital Lease Obligations, Current
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Capital Lease Obligations, Current of $9.82 million as of 2018-12-31, per its 10-K filed 2020-02-13.
Discontinued › Notes › Leases
us-gaap:CapitalLeaseObligationsCurrent · last filed 2020-02-13
- 2018-12-31: Capital Lease Obligations, Current $9.82M.
- 2018-09-30: Capital Lease Obligations, Current $11.51M.
- 2018-06-30: Capital Lease Obligations, Current $15.06M.
- 2018-03-31: Capital Lease Obligations, Current $16.92M.
| Period end | Capital Lease Obligations, Current |
|---|---|
| 2018-12-31 | $9.82M 10-K · filed 2020-02-13 |
| 2018-09-30 | $11.51M 10-Q · filed 2018-10-25 |
| 2018-06-30 | $15.06M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $16.92M 10-Q · filed 2018-04-27 |
| 2017-12-31 | $22.53M 10-K · filed 2019-02-13 |
| 2017-09-30 | $19.88M 10-Q · filed 2017-10-30 |
| 2017-06-30 | $18.18M 10-Q · filed 2017-07-28 |
| 2017-03-31 | $19.27M 10-Q · filed 2017-04-28 |
| 2016-12-31 | $19.43M 10-K · filed 2018-02-15 |
| 2016-09-30 | $17.77M 10-Q · filed 2016-10-31 |
| 2016-06-30 | $17.45M 10-Q · filed 2016-08-01 |
| 2016-03-31 | $17.29M 10-Q · filed 2016-05-03 |
| 2015-12-31 | $15.54M 10-K · filed 2017-02-23 |
| 2015-09-30 | $14.15M 10-Q · filed 2015-10-30 |
| 2015-06-30 | $13.92M 10-Q · filed 2015-08-04 |
| 2015-03-31 | $19.67M 10-Q · filed 2015-05-04 |
| 2014-12-31 | $17.81M 10-K · filed 2016-02-16 |
| 2014-09-30 | $18.12M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $19.71M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $18.32M 10-Q · filed 2014-05-05 |
| 2013-12-31 | $16.89M 10-K · filed 2015-02-13 |
| 2013-09-30 | $14.43M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $10.66M 10-Q · filed 2013-08-02 |
| 2013-03-31 | $8.30M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $13.71M 10-K · filed 2014-02-11 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |